Business Context and Reporting Period
The filing is MultiPlan Corporation’s unaudited Form 10-Q for the three months ended March 31, 2024. The request identifies Claritev Corp., but the provided filing is for MultiPlan Corporation (NYSE: MPLN). MultiPlan provides data analytics and technology-enabled healthcare cost-management, payment-integrity and decision-science solutions to healthcare payors.
The company reports as a single U.S. operating segment. Its principal revenue categories are Network-Based Services, Analytics-Based Services, and Payment and Revenue Integrity Services.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $234.5 million | $236.6 million | Down 0.9% |
| Operating income (loss) | $(486.4) million | $46.9 million | Down $533.4 million |
| Net income (loss) | $(539.7) million | $0.2 million | Down $539.9 million |
| Basic and diluted EPS | $(0.83) | $0.00 | Unfavorable |
| Adjusted EBITDA | $146.8 million | $156.3 million | Down 6.1% |
| Adjusted EPS | $0.06 | $0.07 | Down $0.01 |
| Cash flow from operations | $49.7 million | $64.2 million | Down 22.6% |
| Capital expenditures | $30.5 million | $23.1 million | Up 32.2% |
Revenue mix included Analytics-Based Services of $160.1 million, Network-Based Services of $46.2 million, and Payment and Revenue Integrity Services of $28.3 million. Potential medical cost savings identified increased 3.0% to approximately $5.7 billion on $41.5 billion of medical charges processed.
The company ended the quarter with $58.7 million of cash and cash equivalents and $10.5 million of restricted cash. Revolving credit availability was $442.1 million, including $7.9 million of letters-of-credit utilization. Long-term debt, net, was $4.511 billion, with an annualized weighted-average cash interest rate of 6.82%. The Term Loan B interest rate was 9.86% at March 31, 2024.
Net cash used in financing activities was $31.5 million, including $14.9 million for repurchases of Senior Convertible PIK Notes, $10.4 million for share repurchases, and $3.3 million of Term Loan B repayments. Total cash, cash equivalents and restricted cash declined by $12.3 million during the quarter to $69.2 million.
Material Changes Versus the Prior Comparable Period
- Revenue declined modestly because Network-Based Services revenue fell $11.0 million, or 19.3%, partly offset by 5.0% growth in Analytics-Based Services and 4.8% growth in Payment and Revenue Integrity Services.
- Management attributed part of the Network-Based Services decline to customer and program attrition, lower medical savings on percentage-of-savings claims, and reduced claims volumes resulting from a cyberattack affecting a major healthcare claims clearinghouse.
- Costs of services increased 9.5% to $60.1 million, general and administrative expenses increased 10.8% to $34.9 million, and depreciation increased 15.3% to $21.0 million.
- The company recorded a $519.1 million impairment charge, comprising $516.4 million of goodwill impairment and $2.7 million of trade-name impairment. The charge followed significant declines in the stock price and market capitalization, a higher discount rate, and lower EBITDA multiples.
- Goodwill declined from $3.829 billion at December 31, 2023 to $3.313 billion at March 31, 2024. Management stated that the reporting unit’s carrying value equaled its estimated fair value after the impairment, creating potential risk of additional impairment if conditions change.
- Adjusted EBITDA declined despite the impairment being excluded from the non-GAAP measure, reflecting weaker revenue and higher operating costs.
- The company repurchased and cancelled $21.1 million principal amount of Senior Convertible PIK Notes and recognized a $5.9 million gain on extinguishment of debt. In Q1 2023, it repurchased $137.8 million of 5.750% Notes and recorded a $36.8 million gain.
- The company repurchased 10.2 million shares for $10.4 million during the quarter. The remaining authorization under the $100 million program was $74.4 million at March 31, 2024.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide a clear quantitative revenue, earnings, or adjusted EBITDA forecast. Management stated that available cash, operating cash flow, and revolving-credit capacity are expected to provide sufficient liquidity for the next twelve months and the long term, but noted that future liquidity depends on operating performance, financing availability, customer activity, and other factors beyond its control.
- Key risks include customer concentration, customer loss, pricing pressure, competition, lower healthcare utilization, reduced claims volumes, cyberattacks, cybersecurity and privacy requirements, regulatory changes, litigation, personnel retention, acquisition integration, and the ability to service substantial indebtedness.
- Three customers represented 25%, 22%, and 8% of 2023 revenue, respectively, according to the filing.
- The company’s $4.5 billion debt burden includes fixed-rate notes, floating-rate Term Loan B, and convertible PIK notes due in 2027 and 2028. The convertible notes carry 6.00% cash interest and 7.00% PIK interest and are convertible at a $13.00 conversion price, subject to adjustments.
- The company entered into interest-rate swaps with an $800 million notional value, effective through August 31, 2026, to reduce floating-rate cash-flow volatility.
- The company reported compliance with all debt covenants. Its consolidated first-lien debt-to-consolidated EBITDA ratio was 3.78 times at March 31, 2024.
- Ordinary-course lawsuits, regulatory investigations, and other contingencies remain outstanding. Management does not expect them to have a material adverse effect, but ultimate outcomes cannot be predicted with certainty.
- On March 28, 2024, the NYSE notified the company that its average closing share price was below $1.00 for 30 consecutive trading days. The company is considering alternatives, including a reverse stock split, and stated that stockholder approval may be required by September 28, 2024 to regain compliance.
- Disclosure controls and procedures were determined to be effective as of March 31, 2024, and no material change in internal control over financial reporting was reported.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for MultiPlan Corporation, not Claritev Corp.
- Assess whether the $519.1 million impairment is an isolated accounting charge or signals sustained deterioration in expected operating performance and market valuation.
- Monitor Network-Based Services volumes, customer attrition, healthcare claims activity, and any continuing effects from the healthcare clearinghouse cyberattack.
- Evaluate liquidity and refinancing risk relative to approximately $4.5 billion of debt, scheduled maturities, interest rates, and only $442.1 million of revolver availability.
- Track compliance with the NYSE minimum-price requirement and the potential effect of a reverse stock split on shareholders.
- Review customer concentration, contract renewals, pricing trends, and the extent to which potential medical savings convert into recognized revenue.
- Reconcile adjusted EBITDA and adjusted EPS to GAAP results, particularly the exclusions for impairment, amortization, stock compensation, debt extinguishment gains, and other items.